108 related articles for article (PubMed ID: 1546713)
1. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma.
Solary E; Guiguet M; Zeller V; Casasnovas RO; Caillot D; Chavanet P; Guy H; Mack G
Am J Hematol; 1992 Mar; 39(3):163-71. PubMed ID: 1546713
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
Nachbaur DM; Herold M; Maneschg A; Huber H
Ann Hematol; 1991; 62(2-3):54-8. PubMed ID: 2031968
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
Thaler J; Fechner F; Herold M; Huber H
Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
[TBL] [Abstract][Full Text] [Related]
7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
8. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
9. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
10. Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.
Morell A; Riesen W
Acta Haematol; 1980; 64(2):87-93. PubMed ID: 6159767
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
12. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
14. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
Zhang XG; Bataille R; Widjenes J; Klein B
Cancer; 1992 Mar; 69(6):1373-6. PubMed ID: 1540875
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
17. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
18. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
19. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
20. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
Bataille R; Grenier J; Sany J
Blood; 1984 Feb; 63(2):468-76. PubMed ID: 6362753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
